Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001925810 | SCV002180027 | uncertain significance | Dyskeratosis congenita, autosomal dominant 6 | 2021-11-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with ACD-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 155 of the ACD protein (p.Cys155Ser). |
Ambry Genetics | RCV002334880 | SCV002639918 | uncertain significance | Inborn genetic diseases | 2022-06-11 | criteria provided, single submitter | clinical testing | The p.C155S variant (also known as c.464G>C), located in coding exon 2 of the ACD gene, results from a G to C substitution at nucleotide position 464. The cysteine at codon 155 is replaced by serine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |